Puma Biotechnology
PBYI
137 hedge funds and large institutions have $1.69B invested in Puma Biotechnology in 2014 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 53 increasing their positions, 39 reducing their positions, and 32 closing their positions.
98% more call options, than puts
Call options by funds: $48.3M | Put options by funds: $24.4M
36% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 39
1.32% more ownership
Funds ownership: 83.44% → 84.76% (+1.3%)
0% more funds holding
Funds holding: 137 → 137 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 32
36% less capital invested
Capital invested by funds: $2.61B → $1.69B (-$928M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$32.6M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$23.9M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$21.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.1M |
| 5 |
O
OrbiMed
New York
|
+$15.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$55.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$52.8M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$19.4M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$18.6M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$17.9M |
PBYI Hedge Fund Activity: Q2 2014 in Review
137 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2014, worth a combined $1.69B — down 36% from $2.61B a quarter earlier.
Fund positioning in PBYI was balanced in Q2 2014: 32 funds opened new positions, 32 closed out, 53 added to existing stakes and 39 trimmed.
The largest buyer was BB Biotech, adding an estimated $32.6M. The largest seller was Fidelity Investments, cutting an estimated $55.1M.
- 137 institutional investors held Puma Biotechnology (PBYI) as of Q2 2014, unchanged from Q1 2014.
- Funds reported $1.69B of Puma Biotechnology stock for Q2 2014, down 36% quarter-over-quarter.
- 32 funds opened new Puma Biotechnology positions in Q2 2014 and 32 closed out, a net change of 0 holders.
- The largest Puma Biotechnology buyer in Q2 2014 was BB Biotech, an estimated $32.6M added.
- The largest Puma Biotechnology seller in Q2 2014 was Fidelity Investments, an estimated $55.1M sold.
Based on aggregated 13F filings for Q2 2014.